-
平臺(tái)編號(hào)：bio-68434
-
國(guó)際編號(hào)：ATCC CRL-12444
-
細(xì)胞信息： CHO DP-12
-
規(guī)格：frozen
-
用途：ATCC原裝細(xì)胞
-
服務(wù)費(fèi)用：
加載中…… - 訂購(gòu)
-
注意事項(xiàng)：僅用于科學(xué)研究或者工業(yè)應(yīng)用等非醫(yī)療目的不可用于人類或動(dòng)物的臨床診斷或治療，非藥用，非食用（產(chǎn)品信息以出庫(kù)為準(zhǔn)）
CHO DP-12
器官來源：卵巢
ATCC Number：CRL-12444?
數(shù)量：大量
細(xì)胞形態(tài)：成纖維樣
免疫類型：human IgG1
是否是腫瘤細(xì)胞：0
物種來源：倉(cāng)鼠
運(yùn)輸方式：凍存運(yùn)輸
生長(zhǎng)狀態(tài)：貼壁生長(zhǎng)
規(guī)格：0.1ml Designations: CHO DP-12 clone#1933 [CHO DP-12, clone#1933 aIL8.92 NB 28605/12]
Depositors: ?Genetech, Inc.
Isotype: human IgG1
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:adherent
Organism: Cricetulus griseus
Morphology:fibroblast
Source: Organ: ovary
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Comments:The clone#1933 aIL8.92 NB 28605/12 cell line was derived by co-transfecting the CHO cell line DP-12 using Lipofection with the vector p6G4V11N35A.choSD.9 designed to coexpress variable light and heavy regions of the murine 6G4.2.5 monoclonal antibody (ATCC -HB-11722). Clones were selected in methotrexate. The cells are reported to produce 150 mg/L recombinant human anti-IL-8. Both the clone#1933 (ATCC -CRL-12444) and clone#1934 (ATCC CRL-12445 ) antibodies inhibit IL-8 binding to human neutrophils. They also show equivalent neutralizing capabilities to inhibiting IL-8 mediated human neutrophil chemotaxis. The mammalian expression plasmid, p6G4V11N35AchoSD.9 (identified as p6G425V11N35A.choSD) is deposited as ATCC 209552 .
Propagation: ATCC complete growth medium: Dulbecco's modified Eagle's medium with 4 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate and 4.5 g/L glucose supplemented with 200 nM MTX (Methotrexate), Trace elements A and B from Mediatech, 0.002 mg/ml rhInsulin and 10% fetal bovine serum.
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0°C
Subculturing: Protocol:
Subcultivation Ratio: A subcultivation ratio of 1:3 to 1:4 is recommended
Medium Renewal: Two to three times weekly
Preservation: Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2002
recommended serum:ATCC 30-2020
References: 71467: Hsei V, et al. Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates. US Patent 6,468,532 dated Oct 22 2002
71468: Hsei V, et al. Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates. US Patent 6,458,355 dated Oct 1 2002
71469: Gonzalez TN, et al. Humanized anti-IL-8 monoclonal antibodies. US Patent 6,133,426 dated Oct 17 2000
71470: Gonzalez TN, et al. Humanized anti-IL-8 monoclonal antibodies. US Patent 6,117,980 dated Sep 12 2000
71471: Gonzalez TN, et al. Nucleic acids encoding humanized anti-IL-8 monoclonal antibodies. US Patent 6,025,158 dated Feb 15 2000
ATCC Number：CRL-12444?
數(shù)量：大量
細(xì)胞形態(tài)：成纖維樣
免疫類型：human IgG1
是否是腫瘤細(xì)胞：0
物種來源：倉(cāng)鼠
運(yùn)輸方式：凍存運(yùn)輸
生長(zhǎng)狀態(tài)：貼壁生長(zhǎng)
規(guī)格：0.1ml Designations: CHO DP-12 clone#1933 [CHO DP-12, clone#1933 aIL8.92 NB 28605/12]
Depositors: ?Genetech, Inc.
Isotype: human IgG1
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:adherent
Organism: Cricetulus griseus
Morphology:fibroblast
Source: Organ: ovary
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Comments:The clone#1933 aIL8.92 NB 28605/12 cell line was derived by co-transfecting the CHO cell line DP-12 using Lipofection with the vector p6G4V11N35A.choSD.9 designed to coexpress variable light and heavy regions of the murine 6G4.2.5 monoclonal antibody (ATCC -HB-11722). Clones were selected in methotrexate. The cells are reported to produce 150 mg/L recombinant human anti-IL-8. Both the clone#1933 (ATCC -CRL-12444) and clone#1934 (ATCC CRL-12445 ) antibodies inhibit IL-8 binding to human neutrophils. They also show equivalent neutralizing capabilities to inhibiting IL-8 mediated human neutrophil chemotaxis. The mammalian expression plasmid, p6G4V11N35AchoSD.9 (identified as p6G425V11N35A.choSD) is deposited as ATCC 209552 .
Propagation: ATCC complete growth medium: Dulbecco's modified Eagle's medium with 4 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate and 4.5 g/L glucose supplemented with 200 nM MTX (Methotrexate), Trace elements A and B from Mediatech, 0.002 mg/ml rhInsulin and 10% fetal bovine serum.
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0°C
Subculturing: Protocol:
- Remove culture medium. Keep the floating cells to transfer with attached cells..
- Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.
-
Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37?C to facilitate dispersal. - Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.
- Add appropriate aliquots of the cell suspension to new culture vessels.
- Incubate cultures at 37?C.
Subcultivation Ratio: A subcultivation ratio of 1:3 to 1:4 is recommended
Medium Renewal: Two to three times weekly
Preservation: Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2002
recommended serum:ATCC 30-2020
References: 71467: Hsei V, et al. Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates. US Patent 6,468,532 dated Oct 22 2002
71468: Hsei V, et al. Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates. US Patent 6,458,355 dated Oct 1 2002
71469: Gonzalez TN, et al. Humanized anti-IL-8 monoclonal antibodies. US Patent 6,133,426 dated Oct 17 2000
71470: Gonzalez TN, et al. Humanized anti-IL-8 monoclonal antibodies. US Patent 6,117,980 dated Sep 12 2000
71471: Gonzalez TN, et al. Nucleic acids encoding humanized anti-IL-8 monoclonal antibodies. US Patent 6,025,158 dated Feb 15 2000
